HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation {Nasdaq-Global Market:IMMC}, which is developing and commercializing proprietary cell and molecular-based human diagnostic and life-science research products with an initial focus on cancer, today announced its results of operations for the three months and year ended December 31, 2006 and its guidance estimates for 2007.
